【东方证券：降脂药物市场前景广阔】金十数据2月12日讯，东方证券研报称，全球心血管疾病发病率上升，推动降脂药市场稳定增长。从全球来看，2023年降脂药市场规模为331.2亿美元，预计十年后将达到465.8亿美元。2023年，我国等级医院及零售终端降脂药销售额已突破250亿元，未来有望稳定增长。PCSK9新药来势汹汹，国产药物后来居上。PCSK9抑制剂全球销售额增长势头强劲，国产药物方面，首个PCSK9抑制剂——信达生物的托莱希单抗于2023年8月上市。创新靶点涌现，全球降脂药研发全面提速。由于血脂异常的发病率不断上升且趋于年轻化，降脂药物市场前景广阔。同时，新靶点、新技术路线不断被验证，创新药物的获批亦能驱动市场快速扩容。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.